Endo-anesthesia: a primer.

Authors:
Bazerbachi F; White RM; Forbes N; Goudra B; Abu Dayyeh BK and 2 more

Journal:
Gastroenterol Rep (Oxf)

Publication Year: 2022

DOI:
10.1093/gastro/goac069

PMCID:
PMC9664071

PMID:
36381224

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Gastroenterol Rep (Oxf)

Abbreviation: Gastroenterol Rep (Oxf)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A novel location classification system for Crohn's disease based on small bowel involvement: a bett…
Guo H; Tang J; Qin X and 6 more (2024) - Transparency Score: 3/6
An unusual interventional approach to treat Type 2 Abernethy malformation in children: two case rep…
Yan J; Yin J; Zhang D and 3 more (2024) - Transparency Score: 3/6
Esophageal mucosa exfoliation: a rare case during endoscopic submucosal dissection.
Tang L; Luo R; Wu Z and 2 more (2024) - Transparency Score: 3/6
Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South o…
Pinazo-Bandera JM; Aranda J; García-García AM and 18 more (2024) - Transparency Score: 3/6
Heterogeneity of immune infiltration and immunotherapy in colorectal cancer.
Li Y; Hu J; Zhi M. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Dr Abu Dayyeh: consultant for and received research support/grant from Boston Scientific and USGI Medical; consultant with Metamodix, BFKW, and DyaMx; received research support from Apollo Endosurgery, Spatz Medical, GI Dynamics, Caim Diagnostics, Aspire Bariatrics, and Medtronic; speaker with Johnson & Johnson, Endogastric Solutions, and Olympus. Dr Chandrasekhara: Advisory Board of Interpace Diagnostics; shareholder in Nevakar Corporation; consultant with Covidien LLP."

Evidence found in paper:

"Funding None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025